In 2011, Curis initiated a Phase I clinical trial of IV CUDC-101 in patients with intermediate and high-risk locally advanced head and neck cancer, including patients whose tumor is human papillomavirus (HPV) negative or HPV positive and have at least a 10 pack-years smoking history. The primary objectives of this study are to evaluate the safety, tolerability and MTD of CUDC-101 when administered in combination with standard-of-care of radiation therapy and cisplatin.
About Curis, Inc.
Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. Curis is building upon its previous experiences in targeting signaling pathways, including in the Hedgehog pathway, in its effort to develop proprietary targeted cancer programs. For more information, visit Curis' website at
The Curis, Inc. logo is available at
Curis Cautionary Statement:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding Curis' expectations regarding the potential benefits of the oral formulation of CUDC-101. Forward-looking statements used in this press release may contain the words "believes," "expects," "anticipates," "plans," "seeks," "estimates," "assumes," "will," "may," "could" or similar expressions. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties, assumptions and other important factors that may cause actual results to be materially different from those indicated by such forward-looking statements. For example, Curis may not be able to successfully enroll patients in this Phase I clinical trial or may otherwise experience delays, setbacks and failures in its clinical development of CUDC-101, and the oral tablet form of CUDC-101 may cause unexpected toxicities.
Curis also faces other important risks relating to its business, operations, financial condition and future prospects generally, that are discussed in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2012 and other filings that it periodically makes with the Securities and Exchange Commission.
In addition, any forward-looking statements represent the views of Curis only as of today and should not be relied upon as representing Curis' views as of any subsequent date. Curis disclaims any intention or obligation to update any of the forward-looking statements after the date of this press release whether as a result of new information, future events or otherwise.
CONTACT: Michael P. Gray
Chief Financial and Chief Operating Officer